Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (18754)	2/13/1999 9:57:00 PM
From: Greg22	Read Replies (1) \| Respond to of 23519

VLAD, I think things are starting to look up. I predict that Vivus will be bought out. If you consider that Vivus will be able to make roughly 0.30/share this year, that would translate to a profit of about $10 million. I would say that a fair buyout price would be about 35 times earnings or $350 million, or $11 shares. Most likely a stock swap, and not cash. Why a buyout? Because the ED market is projected to be $5 billion in 5 years. What better way to get into this business than to by Vivus. Vivus has some of the world's leading scientists in the field and has accumulated much research, not to mention gene therapy. If it is determined that a marketing partner cannot increase shareholder value as planned, I think that Vivus will be bought out at $11 share.